DK3325662T3 - Epigenetisk inaktivering af nmt2 - Google Patents
Epigenetisk inaktivering af nmt2 Download PDFInfo
- Publication number
- DK3325662T3 DK3325662T3 DK16826961.1T DK16826961T DK3325662T3 DK 3325662 T3 DK3325662 T3 DK 3325662T3 DK 16826961 T DK16826961 T DK 16826961T DK 3325662 T3 DK3325662 T3 DK 3325662T3
- Authority
- DK
- Denmark
- Prior art keywords
- nmt2
- epigenetic inactivation
- epigenetic
- inactivation
- Prior art date
Links
- 102100023122 Glycylpeptide N-tetradecanoyltransferase 2 Human genes 0.000 title 1
- 101000979544 Homo sapiens Glycylpeptide N-tetradecanoyltransferase 2 Proteins 0.000 title 1
- 230000001973 epigenetic effect Effects 0.000 title 1
- 230000002779 inactivation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194109P | 2015-07-17 | 2015-07-17 | |
| PCT/CA2016/050846 WO2017011907A1 (en) | 2015-07-17 | 2016-07-18 | Epigenetic silencing of nmt2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3325662T3 true DK3325662T3 (da) | 2023-11-27 |
Family
ID=57833648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16826961.1T DK3325662T3 (da) | 2015-07-17 | 2016-07-18 | Epigenetisk inaktivering af nmt2 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11788145B2 (da) |
| EP (1) | EP3325662B1 (da) |
| JP (2) | JP7539760B2 (da) |
| DK (1) | DK3325662T3 (da) |
| ES (1) | ES2964607T3 (da) |
| PL (1) | PL3325662T3 (da) |
| WO (1) | WO2017011907A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140072026A (ko) | 2011-07-22 | 2014-06-12 | 페이실렉스 파마슈티컬스 인코포레이티드 | 암의 합성치사 및 치료 |
| EP3464275B1 (en) | 2016-05-26 | 2024-05-08 | Recurium IP Holdings, LLC | Egfr inhibitor compounds |
| CN106868146B (zh) * | 2017-03-06 | 2020-01-24 | 新乡医学院 | 用于检测与结直肠癌长春新碱耐药相关的miRNA表达的引物、试剂盒、方法及应用 |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| CA3066054A1 (en) | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
| WO2019204758A1 (en) * | 2018-04-20 | 2019-10-24 | Zhiguo Zhang | Compositions and methods for treating glioblastoma by modulating a mgmt enhancer |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| GB201820660D0 (en) | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Cancer treatments |
| GB201820659D0 (en) | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Novel compostions and their use in therapy |
| EP3902917A4 (en) * | 2018-12-27 | 2022-11-30 | bioAffinity Technologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| CN115697374A (zh) * | 2020-05-12 | 2023-02-03 | 得克萨斯州大学系统董事会 | 用于治疗胶质母细胞瘤的方法 |
| GB202014736D0 (en) | 2020-09-18 | 2020-11-04 | Imperial College Innovations Ltd | Novel compounds and their use in therapy |
| GB202017367D0 (en) | 2020-11-02 | 2020-12-16 | Imperial College Innovations Ltd | Novel use |
| CN112516141A (zh) * | 2020-12-07 | 2021-03-19 | 浙江大学 | Cd47表达抑制剂及其与免疫治疗药物联合使用 |
| IL310769A (en) | 2021-08-11 | 2024-04-01 | Oncohost Ltd | Predicting patient response |
| IL314984A (en) * | 2022-03-03 | 2024-10-01 | Pacylex Pharmaceuticals Inc | Oral PCLX-001 for the treatment of human cancer |
| WO2024052684A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2657259A1 (fr) | 1990-01-25 | 1991-07-26 | Adir | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
| US20030180292A1 (en) | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| CA2517629C (en) | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| CN102107008B (zh) | 2003-12-01 | 2013-04-03 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| CN1905864B (zh) | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| EP1718310A4 (en) | 2004-02-06 | 2009-05-06 | Elan Pharm Inc | METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE |
| SI1771474T1 (sl) | 2004-07-20 | 2010-06-30 | Genentech Inc | Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba |
| WO2006086043A2 (en) | 2004-11-23 | 2006-08-17 | Science & Technology Corporation @ Unm | Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults |
| WO2007036025A1 (en) | 2005-09-27 | 2007-04-05 | University Of Saskatchewan | Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosls |
| CN101631466B (zh) | 2006-12-18 | 2013-02-13 | 杰克·阿比瑟 | 新钯络合物体外抑制n-肉豆蔻酰基转移酶活性和体内抑制癌生长 |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| KR20140072026A (ko) | 2011-07-22 | 2014-06-12 | 페이실렉스 파마슈티컬스 인코포레이티드 | 암의 합성치사 및 치료 |
| KR20220040509A (ko) | 2012-10-30 | 2022-03-30 | 페이실렉스 파마슈티컬스 인코포레이티드 | 암의 합성치사 및 치료 |
-
2016
- 2016-07-18 EP EP16826961.1A patent/EP3325662B1/en active Active
- 2016-07-18 DK DK16826961.1T patent/DK3325662T3/da active
- 2016-07-18 PL PL16826961.1T patent/PL3325662T3/pl unknown
- 2016-07-18 WO PCT/CA2016/050846 patent/WO2017011907A1/en active Application Filing
- 2016-07-18 US US15/745,578 patent/US11788145B2/en active Active
- 2016-07-18 ES ES16826961T patent/ES2964607T3/es active Active
- 2016-07-18 JP JP2018502095A patent/JP7539760B2/ja active Active
-
2021
- 2021-10-28 JP JP2021176651A patent/JP2022023186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180208990A1 (en) | 2018-07-26 |
| EP3325662A4 (en) | 2019-01-02 |
| EP3325662A1 (en) | 2018-05-30 |
| WO2017011907A1 (en) | 2017-01-26 |
| PL3325662T3 (pl) | 2024-02-26 |
| US11788145B2 (en) | 2023-10-17 |
| ES2964607T3 (es) | 2024-04-08 |
| JP2018521654A (ja) | 2018-08-09 |
| EP3325662B1 (en) | 2023-08-30 |
| JP2022023186A (ja) | 2022-02-07 |
| JP7539760B2 (ja) | 2024-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3325662T3 (da) | Epigenetisk inaktivering af nmt2 | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3461891T3 (da) | Nedstrømsbehandling af en alkalisk phosphatase | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3154561T3 (da) | Modulering af komplementaktivitet | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3506904T3 (da) | Behandling af demens | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3329007T3 (da) | Ortogonal afblokering af nukleotider | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3201323T3 (da) | Modificering af bakteriofag | |
| DK2897382T3 (da) | Forbedring af binaural kilde | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3289363T3 (da) | Specifik påvisning af clusterin isoformer | |
| DK3073409T3 (da) | Maskering af forskellige indholdstyper | |
| DK3430004T3 (da) | Faststofformer af nilotinibsalte |